PNV 3.28% $2.51 polynovo limited

Ann: FY24 Trading Result (unaudited), page-95

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,201 Posts.
    lightbulb Created with Sketch. 125
    What an impactful performance on increase in Revenue.. ! A lesson probably many biotech as well as companies in general to learn on how an appoint of a CEO with right education and work experience makes change to the future of the company (Sigma is another example).

    Education in Pharmaceutical science which is the core of the industry PNV works and MBA which helps one learn sales, marketing, operations & finance combined with J&J work history in three different country !

    Most Biotech & Medical device companies run by accountant and lawyers on the board (+ HC stock pumpers !) with pathetic promises of performance but no delivery and capital raise every now and then with no tangible results apart form we going phase xx to xxx !



    https://hotcopper.com.au/data/attachments/6331/6331802-b0b93721c5244f644d2740efca8539c2.jpg

 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.